2018 Diabetes Care Guidelines

| Clinical Goals | | | | | | | | |
|---------------------|----------------|--|----------------------------------|--------------------------------------|--|--|--|--|
| | G | lycemic Goal ¹ | Blood Pressure Goal ⁴ | Premeal Glucose Targets ¹ | | | | |
| HgbA ₁ C | <u><</u> 7% | For most diabetics | | 80-120 mg/dL | | | | |
| | < 8% | For h/o severe hypoglycemia, advanced age, advanced micro &/or macro vascular complications, extensive comorbid conditions & long-standing DM when goal difficult to attain despite DSME | <130/80 | | | | | |



| | to attain ac | Spile DSIVIE | | | | | | | | |
|---|-------------------------|--|---|--|---|--|--|--|--|--|
| Standards of Care | | | | | | | | | | |
| Office Visit Frequency | | Lab Work | | | Screenings | | Medications | | | |
| Condition | Schedule | Indicator | Level | Schedule | Туре | Schedule | Туре | Prescribed if: | | |
| Hospitalized | 3-5 days post discharge | 0 1 | >7.0%, or not meeting goal | Every 3 mos | Tobacco Abuse ¹ *offer pharmacological therapy if patient is interested in quitting. e | | Statins ² | (See Table on reverse side of this document) | | |
| Treatment goals NOT being met ³ | Every 3 mos | | <7.0%, or meeting goal | Every 6 mos | cigarettes = not supported as alternative or to facilitate cessation ¹¹ | | empagliflozin or liraglutide ³ | Consider if known cardiovascular disease | | |
| Treatment Goals ARE being met ³ | Every 6 mos | Lipid profile ³ | | If not performed or available within past 12 | Eye Exam ³ | Type 1 (≥5 years) & Type 2 - Every 2 years | Ace Inhibitor ² | In cases of known CVD | | |
| met | | | | months; as needed | PHQ-2 ¹ | Every 12 mos | ACEI, ARB,Thiazide-like | | | |
| Educat | tion | Spot urinary albumin-to-creatinine ratio ³ | Every 12 mos | | <u> </u> | 5 ypc 2 (25 yca.s) | | | | |
| Home blood pressure monitoring ⁵ | | Serum Creatinine & estimated GFR ¹ | | Every 12 mos | Neuropathy ³ | & DM Type 2 - Annually | dihydropyridine calcium channel blocker ³ | HTN and negative albuminuria | | |
| Monitoring carbohydrate intake ¹ | | Serum Potassium (if on ACE, ARB or diuretic) ¹ | | Every 12 mos | Sleep patterns ³ | Each visit | | | | |
| Medication administration (insulin or oral meds) ¹ | | ALT ¹ | | Every 12 months | Foot Exam ¹ | Normal-annual; Abnormal-each visit | the non-pregnant | Recommended if urinary albumin 30-299 mg/g; Strongly recommended if urinary albumin ≥300 mg/g | | |
| Blood glucose monitoring ¹ | | B12 Level (if on long term metformin therapy) ³ | | As needed | Cormorbities ³ | Each visit | | | | |
| Limit alcohol consumption ¹ | | Thyroid Stimulating Hormone (TSH) - Type 1 diabetics | | Every 12 months | Psychosocial determinants ³ & literacy | Annually & prn | | | | |
| Proper foot care, surveillance, protection (especially if has abnormal foot exam) 1 | | | | | Cardiovascular risk factors ³ | At least annually | Aspirin or clopidogrel (if known ASA allergy) ³ | Known ASCVD (if not contraindicated); increased CV | | |
| Exercise ¹ | | Referrals | | | | | | | | |
| Smoking cessation ¹ | | Туре | Explanation | | | | | | | |
| Weight loss/Weight Management ³ Endocrinology | | | Consider referral if diabetic complications present; All individuals with Type 1 Diabetes; patients with HgbA1c >8 x2 consecutive tests | | | | | | | |
| Immunizations Podiatry ³ History of smoking, lower extremity complications, loss of protective sensation | | | | | | | | | | |
| Per CDC Guidelines | | Nephrology | GFR < 60, anemia, metabolic bone disease, or etiology of kidney disease uncertain | | | | | | | |
| | | Registered Dietitian ²⁰ | For Medical Nutrition Therapy-ALL diabetics (as often as needed to achieve treatment goals) | | | | | | | |
| | | Certified Diabetic Educator ²¹ | For diabetes self management education - group or individual sessions; referral annually for ALL diabetics not meeting A1C goal ***For Adena Care Members, diabetic education is a covered service *** | | | | | | | |
| | | Maternal-Fetal | All diabetic mothers | | | | | | | |
| | | Nurse Navigator ³ | If HgbA ₁ C persistently elevated (>9.0%) after 12 months of intervention; any noted social determinants | | | | | | | |

2018 Diabetes Care Guidelines

| ADA RECOMMENDATIONS FOR STATIN TREATMENT IN DIABETES | | | | | | | |
|--|--|---|--|--|--|--|--|
| AGE | RISK FACTORS | RECOMMENDED STATIN INTENSITY* | Notes | | | | |
| Less than 40 years old | None ASCVD Risk Factor(s)** ASCVD*** | None Moderate or High High | * In addition to lifestyle therapy **ASCVD risk factors include LDL cholesterol | | | | |
| 40-75 Years old | None ASCVD Risk Factors ASCVD ACS & LDL > 50 mg/dL in pts who cannot tolerate high dose statin | Moderate High High Moderate PLUS ezetimibe | >100 mg/dL, high blood pressure, smoking, overweight and obesity, and family history of premature ASCVD ***Overt CVD includes those with previous | | | | |
| Greater than 75 years | None ASCVD Risk Factors ASCVD ACS & LDL > 50 mg/dL in pts who cannot tolerate high dose statin | Moderate Moderate or High High Moderate PLUS ezetimibe | cardiovascular events or acute coronary syndromes | | | | |

References

¹ Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Provider.

Welton, P.K., et al. (November 2017). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Downloaded from http://hyper.ahajournals.org on January 10, 2018.

Shamerican Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018 Jan; 41(Supplement 1): S13-S27. https://doi.org/10.2337/dc18-S002

American Diabetes Association. Standards of Medical Care January 2016.

American Diabetes Association. Standards of Medical Care in Diabetes, 2017. The Journal of Clinical and Applied Research and Education, Volume 40, Supplement 1. (January 2017). Retrieved from https://www.diabetes.org/diabetescare.